OXFORD, England, January 5, 2011 /PRNewswire/ -- Elsevier, the world's leading publisher of scientific, technical and medical information, announced today that it has become the new publisher of the International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) journal Value in Health.
Value in Health ( http://www.elsevier.com/wps/find/journaldescription.authors/724501/description#description) is a multidisciplinary peer-reviewed journal reporting on outcomes research evaluations of medical technologies including pharmaceuticals, biologics, devices, medical procedures, and other health care interventions. The journal is published eight times a year.
The Journal provides a scientific forum for communicating clinical, economic, and patient-reported outcomes research methods and findings, furthering ISPOR's mission that 'society allocates scarce health care resources wisely, fairly, and efficiently. Value in Health is also a sounding board for the discussion of health policy issues related to health economics and outcomes research studies associated with all medical technologies. Topics include budget impact/cost-effectiveness/cost-utility/cost-benefit analysis, health utilities/preferences, patient-reported outcomes/health-related quality of life/health status research, health technology assessment, disease management, with study designs (prospective, retrospective, observational and clinical trials, and modeling), and critical reviews of existing literature.
ISPOR (http://www.ispor.org/) is a (not-for-profit) member driven, international, educational and scientific organization promoting the science of pharmacoeconomics and outcomes research (clinical, economic, and patient-reported outcomes) and the translation of outcomes research into health care decisions. ISPOR has over 5,500 active members from 86 countries and 3,300 members in its 42 regional chapters totaling over 8,900 members.
ISPOR represents researchers and practitioners including pharmacists, physicians, economists, public health and other professionals involved in pharmacoeconomic analysis and health outcomes assessment as well as users of this information in health care decisions in government, hospitals, managed care, and pharmacy benefit design organizations.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com/) and Cell (http://www.cell.com/), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect (http://www.sciencedirect.com/), SciVerse Scopus (http://www.scopus.com/), Reaxys (https://www.reaxys.com/), MD Consult (http://www.mdconsult.com/) and Nursing Consult (http://www.nursingconsult.com/), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com/) and MEDai's Pinpoint Review ( http://www.medai.com/), which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com/) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC ( http://www.reedelsevier.com/), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
(Due to the length of some of the URLs, it may be necessary to copy and paste the hyperlink into your Internet browser's URL address field. Remove the space if one exists.)
Media Contact Mustak Kothia firstname.lastname@example.org +44(0)20-7424-4404